State Street Corp. Updates Passive Stake in Intellia Therapeutics
Ticker: NTLA · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1652130
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds Intellia stock, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Intellia Therapeutics Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued passive investment in the gene-editing company. This matters to investors because it confirms a large institutional holder's ongoing interest, potentially signaling confidence in Intellia's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
This filing confirms State Street Corporation's continued institutional ownership in Intellia Therapeutics, which can be a positive signal for other investors regarding the stock's stability and long-term potential.
Risk Assessment
Risk Level: low — This is a routine amendment by a large institutional investor, indicating a passive stake and not suggesting any immediate risk or significant change in company control.
Analyst Insight
An investor should note that a major institution like State Street Corporation maintains a passive stake in Intellia Therapeutics, which can be a sign of long-term confidence, but this filing alone doesn't provide details on the size of the stake or any changes in it, so further investigation into their holdings or Intellia's fundamentals would be prudent.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Intellia Therapeutics, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- 45826J105 (other) — the CUSIP number for Intellia Therapeutics common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by the 'FORM TYPE: SC 13G/A' and 'AMENDED FILING' in the document.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as explicitly stated under '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION'.
What is the subject company whose securities are being reported?
The subject company is INTELLIA THERAPEUTICS INC, as identified under 'NAME OF ISSUER: INTELLIA THERAPEUTICS INC'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the common stock of Intellia Therapeutics Inc. is 45826J105, as stated under 'CUSIP NUMBER: 45826J105'.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as indicated by 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: 12/31/2023'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Intellia Therapeutics, Inc. (NTLA).